<DOC>
	<DOCNO>NCT02093741</DOCNO>
	<brief_summary>This Post-Authorization Safety Surveillance ( PASS ) study design collect data safety effectiveness ADVATE reconstitute 2 mL Sterile water injection ( SWFI ) routine clinical practice child 12 year age . This surveillance study post-licensure commitment ADVATE reconstitute 2 mL SWFI .</brief_summary>
	<brief_title>ADVATE 2 mL Post-Authorization Safety Surveillance ( PASS )</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe moderately severe hemophilia A ( baseline Factor VIII ( FVIII ) ≤ 2 % ) ≤12 year age Participant 's legally authorize representative ( ) provide write informed consent Participant prescribe ADVATE receive ADVATE reconstitute 2 mL sterile water injection ( SWFI ) Documented history prior exposure ADVATE Documented evidence negative inhibitor test result ≤10 EDs prior study entry Known hypersensitivity active substance excipients Known allergic reaction mouse hamster proteins Participant requirement major surgical procedure time enrollment Participant prior exposure FVIII concentrate Participant currently treat immune tolerance induction ( ITI ) regimen Participant diagnose inherit acquire hemostatic defect hemophilia A ( eg , qualitative platelet defect von Willebrand disease ) Participant participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device PASS registry course study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>